Lenglet, Aurelie
Rahali, Mohamad Ali
Sauvage, François-Ludovic
Liabeuf, Sophie
Choukroun, Gabriel
Essig, Marie
El Balkhi, Souleiman
Massy, Ziad A.
Article History
Accepted: 17 May 2021
First Online: 8 June 2021
Change Date: 6 August 2021
Change Type: Update
Change Details: The online published version of this article was revised as the first Author’s name had to be corrected.
Declarations
:
: The study was funded by a grant from the French Government’s Inter-Regional Hospital Research Program (PHRC IR08: 2008-004673-17).
: Ziad A. Massy reports grants and Congress Travel support from Amgen, Baxter, Otsuka, and Sanofi-Genzyme, grants from the French Government, MSD, GSK, Lilly, and FMC, and Receipt of honoraria or consultation fees for the Charities from Daichi and Astellas, outside the submitted work.
: The study protocol was approved by a local investigational review board (CPP Nord Ouest II, Amiens, France; reference: 2008-004673-17) and implemented in accordance with the ethical principles of the Declaration of Helsinki (ClinicalTrials.gov registration number: NCT01011699).
: All participants gave their written agreement to participate in the study.
: All participants gave their written agreement to publication of the study data.
: Not applicable.
: Not applicable.
: Each author contributed intellectual content. ZM and SLB conceived the research idea; AL drafted the manuscript, performed the statistical analysis, and analyzed the data; MAR, JLS, and SLB performed the albumin carbamylation assays; all authors performed a critical analysis of the manuscript, ZM supervised the study.